CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?

被引:0
|
作者
Sakach, Elizabeth [1 ]
Keskinkilic, Merve [2 ]
Wood, Sarah [1 ]
Canning, Madison [1 ]
Kalinsky, Kevin [1 ]
机构
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Dokuz Eylul Univ, Dept Med Oncol, Fac Med, Izmir, Turkiye
关键词
CDK4/6; inhibitor; Hormone therapy; Metastatic breast cancer; Endocrine resistance; ctDNA; ADVANCED BREAST-CANCER; RIBOCICLIB PLUS FULVESTRANT; DOUBLE-BLIND; RESISTANCE; THERAPY; PALBOCICLIB; WOMEN; TRIAL; MULTICENTER; PROGRESSION;
D O I
10.1007/s11864-023-01109-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER-2-) metastatic breast cancer (MBC) is the most common subtype of breast cancer. Due to therapeutic advances with molecularly targeted therapies, the prognosis for patients with metastatic disease has improved significantly. The advent of CDK4/6 inhibitors (CDK4/6i) has changed the treatment paradigm for patients with HR+HER2-MBC. CDK4/ 6i allowed for marked improvement in overall survival, delaying the time to chemotherapy initiation, and improved quality of life for our patients. Efforts are now focused on the best approach(es) for patients after progression on CDK4/6i. Can we further harness the benefit of CDK4/6i in novel combinations at the time of progression? Should we continue CDK4/6i or proceed other novel agents or endocrine therapies? As we advance our treatment strategies for HR+HER2-MBC, there is no longer a one-size-fits-all model, but instead a multifaceted and personalized approach lending to improved outcomes for our patients.
引用
收藏
页码:1103 / 1119
页数:17
相关论文
共 50 条
  • [1] CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
    Elizabeth Sakach
    Merve Keskinkilic
    Sarah Wood
    Madison Canning
    Kevin Kalinsky
    Current Treatment Options in Oncology, 2023, 24 (9) : 1103 - 1119
  • [2] CDK4/6 inhibition in early and metastatic breast cancer: A review
    de Groot, A. F.
    Kuijpers, C. J.
    Kroep, J. R.
    CANCER TREATMENT REVIEWS, 2017, 60 : 130 - 138
  • [3] The transcriptome of CDK4/6 inhibition
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    AGING-US, 2017, 9 (08): : 1859 - 1860
  • [4] Unexpected Outcomes of CDK4/6 Inhibition
    Choi, Yoon Jong
    Sicinski, Piotr
    ONCOTARGET, 2013, 4 (02) : 176 - 177
  • [5] Resistance mechanisms to CDK4/6 Inhibition
    O'Leary, Ben
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 589 - 589
  • [6] CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma
    Olanich, Mary E.
    Sun, Wenyue
    Hewitt, Stephen M.
    Abdullaev, Zied
    Pack, Svetlana D.
    Barr, Frederic G.
    CANCER RESEARCH, 2015, 75
  • [7] Application of CDK4/6 inhibition therapies to PDACs
    Zhang, Yuanyuan
    CANCER SCIENCE, 2023, 114 : 1937 - 1937
  • [8] CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
    Olanich, Mary E.
    Sun, Wenyue
    Hewitt, Stephen M.
    Abdullaev, Zied
    Pack, Svetlana D.
    Barr, Frederic G.
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4947 - 4959
  • [9] Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
    Alvarez-Fernandez, Monica
    Malumbres, Marcos
    CANCER CELL, 2020, 37 (04) : 514 - 529
  • [10] MCL PATIENTS RESPOND TO CDK4/6 INHIBITION
    不详
    CANCER DISCOVERY, 2012, 2 (04) : 300 - 300